Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-34 (Cancelled).

35. (New): A pharmaceutical composition, which composition comprises:

5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and

a pharmaceutically acceptable carrier therefor,

wherein said composition provides a modified release of at least one of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and said metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and

wherein the composition comprises a disintegrating matrix, a non-disintegrating matrix or an erodable matrix.

36. (New) The pharmaceutical composition according to claim 35, wherein the release of metformin hydrochloride, or a pharmaceutically acceptable solvate thereof is modified by the composition.

37. (New) The pharmaceutical composition according to claim 35, wherein the release of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; is modified by the composition.

38. (New) The pharmaceutical composition according to claim 35, wherein the composition comprises a disintegrating matrix.

39. (New) The pharmaceutical composition according to claim 35, wherein the composition comprises a non-disintegrating matrix.

40. (New) The pharmaceutical composition according to claim 35, which is a single or a multi-layer tablet.

41. (New) The pharmaceutical composition according to claim 35, wherein the composition is a multi-layer tablet.

42. (New) The pharmaceutical composition according to claim 41, wherein one layer of the multi-layer tablet provides a sustained release of at least one of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

43. (New) The pharmaceutical composition according to claim 35, wherein the metformin is present in an amount between 100 to 1000mg.

44. (New) The pharmaceutical composition according to claim 35, wherein the 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is present in an amount of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg.

45. (New) The pharmaceutical composition according to claim 35, wherein the non-disintegrating matrix comprises a methacrylic acid copolymer, cellulose acetate, or hydroxypropyl methylcellulose phthalate.

46. (New) The pharmaceutical composition according to claim 45, wherein the methacrylic acid copolymer is ammonio methacrylic acid copolymer Type A, ammonio methacrylic acid copolymer Type B, methacrylic acid copolymer Type C, or a combination thereof.

47. (New) The pharmaceutical composition according to claim 35, wherein the disintegrating matrix comprises a methacrylic acid copolymer, methylcellulose or hydroxypropyl methylcellulose having a nominal viscosity of 4000.

48. (New) The pharmaceutical composition according to claim 47, wherein the methacrylic acid copolymer is methacrylic acid copolymer Type C.

49. (New) The pharmaceutical composition according to claim 40, wherein the tablet is further coated with a gastric resistant polymer.

50. (New) The pharmaceutical composition according to claim 49, wherein the gastric resistant polymer is selected from a methacrylic acid copolymer, cellulose acetate phthalate, polyvinyl acetate phthalate, or hydroxypropyl methylcellulose phthalate.

51. (New) The pharmaceutical composition according to claim 50, wherein the methacrylic acid copolymer is methacrylic acid copolymer Type C.

52. (New) The pharmaceutical composition according to claim 40, wherein the tablet is further coated with a semi-permeable membrane.

53. (New) The pharmaceutical composition according to claim 52, wherein the semi-permeable membrane is a methacrylic acid copolymer, ethylcellulose, or cellulose acetate.

54. (New) The pharmaceutical composition according to claim 53, wherein the methacrylic acid copolymer is ammonio methacrylic acid copolymer Type B.

55. (New): A pharmaceutical composition comprising:

5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof,

metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and

a pharmaceutically acceptable carrier therefor,

wherein said composition provides a modified release of at least one of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and

said metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and

wherein the composition comprises a core coated with a gastric resistant polymer.

56. (New) The pharmaceutical composition according to claim 55, wherein the core is a tablet or a pellet.

57. (New) The pharmaceutical composition according to claim 55, wherein the gastric resistant polymer is selected from a methacrylic acid copolymer, cellulose acetate phthalate, polyvinyl acetate phthalate, or hydroxypropyl methylcellulose phthalate.

58. (New) The pharmaceutical composition according to claim 55, wherein the a methacrylic acid copolymer is methacrylic acid copolymer Type C.

59. (New) The pharmaceutical composition according to claim 55, wherein the release of metformin hydrochloride, or a pharmaceutically acceptable solvate thereof is modified by the composition.

60. (New) The pharmaceutical composition according to claim 59, wherein the metformin is present in an amount between 100 to 1000mg.

61. (New) The pharmaceutical composition according to claim 55, wherein the release of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; is modified by the composition.

62. (New) The pharmaceutical composition according to claim 61, wherein the 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is present in an amount of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg.

63. (New) The pharmaceutical composition according to claim 55, wherein the core further comprises a matrix to provide a modified release of at least one of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and

metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

64. (New) The pharmaceutical composition according to claim 63, wherein the matrix provides for a sustained release of the active agent.

65. (New) The pharmaceutical composition according to claim 64, wherein the matrix is a disintegrating matrix, a non-disintegrating matrix or an erodable matrix.

66. (New) The pharmaceutical composition according to claim 65, wherein the non-disintegrating matrix comprises a methacrylic acid copolymer, cellulose acetate, or hydroxypropyl methylcellulose phthalate.

67. (New) The pharmaceutical composition according to claim 65, wherein the disintegrating matrix comprises a methacrylic acid copolymer, methylcellulose or hydroxypropyl methylcellulose having a nominal viscosity of 4000.

68. (New) The pharmaceutical composition according to claim 56, wherein the tablet core is multi-layer tablet.

69. (New) The pharmaceutical composition according to claim 68, wherein one layer of the multi-layer tablet, further comprises a matrix to provide a modified release of at least one of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and s metformin, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

70. (New) The pharmaceutical composition according to claim 69, wherein the matrix provides for a sustained release of the active agent.

71. (New) The pharmaceutical composition according to claim 70, wherein the matrix is a disintegrating matrix, a non-disintegrating matrix or an erodable matrix.

72. (New) The pharmaceutical composition according to claim 71, wherein the non-disintegrating matrix comprises a methacrylic acid copolymer, cellulose acetate, or hydroxypropyl methylcellulose phthalate.

73. (New) The pharmaceutical composition according to claim 71, wherein the disintegrating matrix comprises a methacrylic acid copolymer, methylcellulose or hydroxypropyl methylcellulose having a nominal viscosity of 4000.

74. (New) The pharmaceutical composition according to claim 73, wherein the methacrylic acid copolymer is methacrylic acid copolymer Type C.

75. (New) A pharmaceutical composition according to claim 35, comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; metformin hydrochloride, or a pharmaceutically acceptable solvate thereof; methacrylic acid copolymer Type C, lactose monohydrate, and ammonio methacrylic acid copolymer Type B.

76. (New) A pharmaceutical composition according to claim 35, wherein the composition is a bilayer tablet comprising:

a first layer comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, methacrylic acid copolymer Type C, lactose monohydrate, and ammonio methacrylic acid copolymer Type B; and

a second layer comprising metformin hydrochloride, or a pharmaceutically acceptable solvate thereof; polyvinyl pyrrolidone and magnesium stearate.

77. (New) A pharmaceutical composition according to claim 55, wherein the composition is a capsule containing multiple pellet cores, said cores comprising:

5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; metformin hydrochloride, or a pharmaceutically acceptable solvate thereof; and microcrystalline cellulose,

wherein said pellet cores are coated with methacrylic acid copolymer Type C.